| 体外研究: |
CEP-37440 (0-3000 nM; 0-192 h) decreases the proliferation of inflammatory breast cancer (IBC) cells in a dose-dependent manner. CEP-37440 (1000 nM; 0-120 h) decreases phospho-FAK1 (Tyr 397) and maintains its low level over time in FC-IBC02, SUM 190, and KPL4. CEP-37440 (0-3000 nM; Sup-M2 and Karpas-299 cells) induces proapoptotic caspases in a dose-dependent manner. Cell Viability Assay Cell Line: FC-IBC02, KPL4, SUM190, MDA-IBC03 and SUM149 cells Concentration: 0, 300, 1000, 2000 and 3000 nM Incubation Time: 0, 24, 48, 72, 96, 120, 144, 168, and 192 hours Result: Reduced the proliferation of three out of five IBC cell lines at low concentration. Inhibited the proliferation almost completely at 3000 nM concentration. Western Blot Analysis Cell Line: FC-IBC02, SUM 190, and KPL4 cells Concentration: 1000 nM Incubation Time: 0, 48, 72, 96 and 120 hours Result: Decreased phospho-FAK1 by half in FC-IBC02, SUM190, and KPL4 cells after 48 hours. |
| 体内研究: |
CEP-37440 (3-55 mg/kg; p.o.; b.i.d and q.d., for 12 d) inhibits breast tumor growth in Sup-M2 xenograftin SCID mice. CEP-37440 (30 mg/kg; p.o; once, for 24 h) inhibits tyrosine phosphorylation in Sup-M2 xenografts mice. CEP-37440 (55 mg/kg; p.o; once, for 24 h) inhibits FAK phosphorylation in CWR22 xenografts in Nude mice. CEP-37440 (1-10 mg/kg; p.o and i.v.; CD-1 mouse, Sprague-Dawley (SD) rats) has good pharmacokinetic parameters. Animal Model: SCID/Beige with Sup-M2 xenografts Dosage: 3 mg/kg (b.i.d), 10 mg/kg (b.i.d), 30 mg/kg (b.i.d and q.d. ), and 55 mg/kg (q.d.) Administration: Oral administration; b.i.d and q.d., for 12 days Result: Inhibited tumor growth in a dose-dependent manner. |